Navigation Links
ZIOPHARM Presents Unique Mechanism Data for Indibulin at AACR

n this class is particularly intriguing. If no neurotoxicity is seen in ongoing clinical trials, indibulin will clearly distinguish itself from other marketed agents in this class."

About ZIO-301

ZIO-301 (indibulin) is a novel synthetic anti-mitotic agent that binds to tubulin, destabilizes microtubulin polymerization, and arrests tumor cell growth at the G2/M phase. Microtubulins are well-established targets for anti-cancer drug development and tubulin-binding drugs such as taxanes and Vinca alkaloids are currently widely used to treat cancer. Indibulin is in a phase I dose-ranging and safety study in Europe. The Company expects to begin phase I/II trials in the U.S. soon.

About ZIOPHARM Oncology, Inc.

ZIOPHARM Oncology, Inc. is a biopharmaceutical company engaged in the development and commercialization of a diverse, risk-sensitive portfolio of in-licensed cancer drugs to address unmet medical needs. The Company applies new insights from molecular and cancer biology to understand the efficacy and safety limitations of approved and developmental cancer therapies and identifies proprietary and related molecules for better patient treatment. For more information, visit www.ziopharm.com.

Forward-Looking Safe Harbor Statement:

This press release contains forward-looking statements for ZIOPHARM Oncology, Inc. that involve risks and uncertainties that could cause the Company's actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These statements are based on current expectations, forecasts and assumptions that are subject to risks and uncertainties, which could cause actual outcomes and results to differ materially from these statements. Among other things, there can be no assurance that any of the Company's development efforts relating to its product candidates will be successful, or such product candidates will be successfully commercialized. Other risk
'"/>




Page: 1 2 3

Related medicine technology :

1. ZIOPHARM to Present at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
2. ZIOPHARM Presents Data Highlighting Oral ZIO-101 at AACR
3. ZIOPHARM Presents Data on Orally Active ZIO-201 at AACR
4. ZIOPHARM Presents ZIO-201 Lymphoma Data at ISH
5. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
6. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
7. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
8. SemBioSys Presents Positive Insulin Data at the American Diabetes Association Conference
9. Tranzyme Pharma Presents Initial Phase IIa Data for its Novel Ghrelin Agonist, TZP-101, in Patients with Diabetic Gastroparesis
10. Novagali Pharma Presents at AACO the Results of its Pivotal Phase III Clinical Trial of Vekacia in Children Suffering From Vernal Keratoconjunctivitis
11. BioLife Solutions Presents Data on CryoStor at International Society for Cellular Therapy Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: ZIOPHARM Presents Unique Mechanism Data for Indibulin AACR
(Date:11/26/2014)... and NEW YORK and ... As the leading distributor of market intelligence, MarketResearch.com is ... report by IQ4I Research and Consultancy focusing on the ... more about IQ4I Research visit: http://www.marketresearch.com/land/publisher.asp?vendorid=4023&progid=86891 . ... Pharmaceutical Ingredients Global Market – Forecast to 2020 ...
(Date:11/26/2014)...  goBalto, Inc., the leading provider of cloud-based clinical ... of Red Herring,s Top 100 Global award. ... award in 2013, marking its emergence as a top ... Herring,s Top 100 Global list has become a mark ... Red Herring editors were among the first to recognize ...
(Date:11/26/2014)... 25, 2014 Nanomix Inc., (Nanomix), ... development of mobile diagnostic tests to enable ... and pre-hospital settings, today announced it has ... The certification was awarded by the British ... leading certification bodies. ISO ...
Breaking Medicine Technology:MarketResearch.com: Active Pharmaceutical Ingredient Market to Reach $175 Billion by 2020 Says IQ4I Report 2MarketResearch.com: Active Pharmaceutical Ingredient Market to Reach $175 Billion by 2020 Says IQ4I Report 3goBalto Selected as a 2014 Red Herring Top 100 Global Company 2goBalto Selected as a 2014 Red Herring Top 100 Global Company 3Nanomix Receives ISO 13485:2003 Certification 2
(Date:11/28/2014)... Dr. Andrew Campbell, one of the ... of Quintessa Aesthetic Center into a third location in ... N1497 Golf Road in Suite 200 and will open ... new Delafield location will offer a variety of ... filler injectables , micro laser peels, chemical peels, ...
(Date:11/28/2014)... November 28, 2014 Secura Consultants, ... few insurance marketing organizations in the country focused ... asset protection marketplace. Secura Consultants is proud to ... Principal Financial Group, a leading global financial company. ... interests. With the ownership interest comes the need ...
(Date:11/28/2014)... November 28, 2014 Not only is ... products free of petroleum, parabens and other cancer-causing agents, ... fund research, education and awareness programs that help in ... and owners have raised an incredible, record-breaking contribution of ... Cure, sales of the Sweet Red Rose Whip Moisturizer ...
(Date:11/28/2014)... York (PRWEB) November 28, 2014 ... ) have now been filed in a New ... metal implants, Bernstein Liebhard LLP reports. , ... Bergen County Superior Court reflects the filing of ... modular-neck hip stems, which were voluntarily recalled on ...
(Date:11/28/2014)... "Most of my life, I have suffered ... said an inventor from Findlay, Ohio. "I thought that there ... my foot, which inspired me to invent this accessory." , ... way to support an injured foot. The sling makes it ... need for crutches. The design redistributes weight so that the ...
Breaking Medicine News(10 mins):Health News:Dr. Andrew Campbell to Expand Quintessa Aesthetic Center into Delafield 2Health News:Secura Consultants Offers Complimentary Buy-Sell Agreement Reviews 2Health News:Éminence Organic Skin Care Donates Record-breaking $30,000 to Breast Cancer Research 2Health News:Éminence Organic Skin Care Donates Record-breaking $30,000 to Breast Cancer Research 3Health News:More than 2,100 Stryker Hip Lawsuits Included in New Jersey Litigation after Settlement Announcement, Bernstein Liebhard LLP Reports 2Health News:More than 2,100 Stryker Hip Lawsuits Included in New Jersey Litigation after Settlement Announcement, Bernstein Liebhard LLP Reports 3
... works, the greater his chances for high blood pressure, a new ... at the// University of California, Irvine analyzed more than 24,000 people ... found that people who worked 40 hours a week are 14 ... who work under 39 hours a week. Those who work 41 ...
... from Rensselaer Polytechnic Institute in Troy, N.Y., and the University ... the host receptors where anthrax toxin attaches in the body. ... bind to multiple sites on the host receptor making it ... site. The researchers found that the new approach led ...
... doctors were stranded for days at the Charity Hospital, when ... of the storm, Charles Gibson reports from that hospital. ... might think you're in a warehouse or some kind of ... ,Charity Hospital served the poor and uninsured people ...
... conjoined twins were separated after a lengthy surgery. 3 weeks ... to their father, it is an indication of their recovery., ... were conjoined at the trunk and shared several internal organs, ... various medical complications caused by the only kidney, the surgery ...
... draw a little closer in understanding the evolution of the ... be more infectious to people. ,According to ... influenza strains from the common human influenza. This conclusion follows ... type flu viruses. This analysis will also aid scientists trace ...
... the Northern Territory Government’s decision to fund rotavirus ... to follow suit and help// protect vulnerable children ... came after the Federal Government’s Pharmaceutical Benefits Advisory ... cost-effective to provide the rotavirus vaccine to all ...
Cached Medicine News:Health News:Inhibitor That Blocks Host Receptors Found To be Effective In Treating Anthrax 2Health News:Conjoined twins doing well after separation 2Health News:Understanding the Evolution of Viruses a little more Clearly 2
Lumbar Allograft with Osteoactive advantage. Promotes bone formation and faster incorporation. Derived from the proven technology behind Grafton DBM. Maintains structural integrity and strength....
... offers strength and radiolucent capabilities for ... titanium microdiscectomy system for microscope-aided repair ... less invasive procedures with reduced patient ... provide low profile, unobstructed retraction capabilities ...
Valin Hemilaminectomy Retractor, self retaining with rack and pinion action....
Karlin Crank Frame Spinal Retractor Set is designed for posterior lumbar and thoracic spine surgery. Arm design allows the blades be pre-positioned in the wound prior to attachment....
Medicine Products: